Balch C M, Murad T M, Soong S J, Ingalls A L, Halpern N B, Maddox W A
Ann Surg. 1978 Dec;188(6):732-42. doi: 10.1097/00000658-197812000-00004.
A multifactorial analysis was used to identify the dominant prognostic variables affecting survival from a computerized data base of 339 melanoma patients treated at this institution during the past 17 years. Five of the 13 parameters examined simultaneously were found to independently influence five year survival rates: 1) pathological stage (I vs II, p = 0.0014), 2) lesion ulceration (present vs absent, p = 0.006), 3) surgical treatment (wide excision vs wide excision plus lymphadenectomy, p = 0.024), 4) melanoma thickness (p = 0.032), and 5) location (upper extremity vs lower extremity vs trunk vs head and neck, p = 0.038). Additional factors considered that had either indirect or no influence on survival rates were clinical stage of disease, age, sex, level of invasion, pigmentation, lymphocyte infiltration, growth pattern, and regression. Most of these latter variables derived their prognostic value from correlation with melanoma thickness, except sex which correlated with location (extremity lesions were more frequent on females, trunk lesions on males). This statistical analysis enabled us to derive a mathematical equation for predicting an individual patient's probability of five year survival. Three categories of risk were delineated by measuring tumor thickness (Breslow microstaging) in Stage I patients: 1) thin melanomas (<0.76 mm) were associated with localized disease and a 100% cure rate: 2) intermediate thickness melanomas (0.76-4.00 mm) had an increasing risk (up to 80%) of harboring regional and/or distant metastases and 3) thick melanomas (>/=4.00 mm) had a 80% risk of occult distant metastases at the time of initial presentation. The level of invasion (Clark's microstaging) correlated with survival, but was less predictive than measuring tumor thickness. Within each of Clark's Level II, III and IV groups, there were gradations of thickness with statistically different survival rates. Both microstaging methods (Breslow and Clark) were less predictive factors in patients with lymph node or distant metastases. Clinical trials evaluating alternative surgical treatments or adjunctive therapy modalities for melanoma patients should incorporate these parameters into their assessment, especially in Stage I (localized) disease where tumor thickness and the anatomical site of the primary melanoma are dominant prognostic factors.
我们使用多因素分析方法,从该机构在过去17年中治疗的339例黑色素瘤患者的计算机数据库中,识别出影响生存的主要预后变量。在同时检查的13个参数中,有5个被发现独立影响五年生存率:1)病理分期(I期与II期,p = 0.0014),2)病变溃疡(存在与不存在,p = 0.006),3)手术治疗(广泛切除与广泛切除加淋巴结清扫,p = 0.024),4)黑色素瘤厚度(p = 0.032),以及5)部位(上肢与下肢与躯干与头颈部,p = 0.038)。其他被认为对生存率有间接或无影响的因素包括疾病的临床分期、年龄、性别、浸润程度、色素沉着、淋巴细胞浸润、生长模式和消退情况。除了性别与部位相关(女性四肢病变更常见,男性躯干病变更常见)外,这些后述变量中的大多数其预后价值来自与黑色素瘤厚度的相关性。这种统计分析使我们能够推导出一个用于预测个体患者五年生存概率的数学方程。通过测量I期患者的肿瘤厚度(Breslow微分期)划分出三类风险:1)薄黑色素瘤(<0.76 mm)与局限性疾病相关,治愈率为100%;2)中等厚度黑色素瘤(0.76 - 4.00 mm)发生区域和/或远处转移的风险增加(高达80%);3)厚黑色素瘤(≥4.00 mm)在初次就诊时隐匿性远处转移的风险为80%。浸润程度(Clark微分期)与生存相关,但预测性不如测量肿瘤厚度。在Clark II级、III级和IV级组中的每一组内,都存在厚度分级,生存率有统计学差异。两种微分期方法(Breslow和Clark)在有淋巴结或远处转移的患者中作为预测因素的作用较小。评估黑色素瘤患者替代手术治疗或辅助治疗方式的临床试验应将这些参数纳入评估,特别是在I期(局限性)疾病中,肿瘤厚度和原发性黑色素瘤的解剖部位是主要的预后因素。